

POSTER PRESENTATION

Open Access

Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer

Ezra EW Cohen^{1*}, Kathleen N Moore², Brian M Slomovitz³, Christine H Chung⁴, Matthew L Anderson⁵, Shannon R Morris⁶, David Mauro⁷, Barbara Burtness⁸

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Background

Approaches that target key HPV genes critical for cancer growth and metastasis may improve survival for individuals diagnosed with carcinomas of the uterine cervix or head and neck. ADXS11-001 is a live attenuated *Listeria monocytogenes* (*Lm*)-listeriolysin O (LLO) immunotherapy bioengineered to secrete an HPV-E7 tumor antigen as a truncated LLO-E7 fusion protein in cells capable of presenting antigen. This results in HPV-specific T-cell generation, reducing tumor protection in the tumor microenvironment. MEDI4736, an anti-programmed death-1 ligand (PD-L1) antibody, blocks the binding of PD-L1 to PD-1 and CD8, and relieves the inhibition of PD-L1-dependent immunosuppressive effects. Inhibition of PD-L1 binding increased the apparent immunologic potency/activity of ADXS11-001 in a preclinical study that showed the combination of ADXS11-011 and an anti-PD-L1 significantly retards tumor growth and prolongs survival in animals.

Methods

This is an open-label, multicenter, 2-part, randomized Phase I/II study (NCT02291055). Patients (≥ 18 years) with squamous/nonsquamous cervical carcinoma or HPV-associated squamous cell cancer of the head and neck who progressed on ≥ 1 prior platinum-based therapy in the recurrent/metastatic setting are eligible. The

primary objective of Phase I is to evaluate the safety and tolerability of ADXS11-001 plus MEDI4736 and select a recommended Phase II dose (RP2D) for the combination. The primary objective of Phase II is to evaluate the tumor response, progression-free survival (PFS), and safety of ADXS11-001 and MEDI4736 as monotherapy and in combination. Exploratory objectives for both phases will evaluate associations between biomarkers of immunologic response with tumor response and PFS. In Phase I, up to 18 patients will receive a fixed dose of ADXS11-001 (1×10^9 colony-forming units [CFU]), while the dose of MEDI4736 will be escalated (starting at 3 mg/kg) according to a standard 3+3 design. In Phase II, patients ($n \approx 48$) will be randomized (1:1:2) to receive either ADXS11-001 (1×10^9 CFU) or MEDI4736 (10 mg/kg) or both at the RP2D; all treatment arms will be stratified by disease. In both phases, ADXS11-001 will be administered every 4 weeks and MEDI4736 every 2 weeks. Patients will receive treatment up to 1 year or until they discontinue due to disease progression or unacceptable toxicity. Efficacy parameters will be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related RECIST criteria, and safety determined using the Common Terminology Criteria for Adverse Events (CTCAE). Enrollment for this study is anticipated in July 2015.

Trial registration

ClinicalTrials.gov identifier NCT02291055.

¹University of California, San Diego Moores Cancer Center, La Jolla, CA, USA
Full list of author information is available at the end of the article

Authors' details

¹University of California, San Diego Moores Cancer Center, La Jolla, CA, USA.

²Stephenson Oklahoma Cancer Center, Oklahoma City, OK, USA. ³University

of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA. ⁴Johns

Hopkins University, Baltimore, MD, USA. ⁵Baylor College of Medicine,

Houston, TX, USA. ⁶Medimmune, LLC, Gaithersburg, MD, USA. ⁷Advaxis, Inc.,

Princeton, NJ, USA. ⁸Yale University School of Medicine, New Haven, CT, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P147

Cite this article as: Cohen *et al.*: Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer. *Journal for ImmunoTherapy of Cancer* 2015 3(Suppl 2):P147.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

